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Background: Asthma is characterized by airway hyper-responsiveness and variable airflow obstruction, in part as a
consequence of hyper-contractile airway smooth muscle, which persists in primary cell culture. One potential
mechanism for this hyper-contractility is abnormal intracellular Ca2+ handling.
Methods: We sought to compare intracellular Ca2+ handling in airway smooth muscle cells from subjects with asthma
compared to non-asthmatic controls by measuring: i) bradykinin-stimulated changes in inositol 1,4,5-trisphosphate (IP3)
accumulation and intracellular Ca2+ concentration, ii) sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) expression, iii)
mechanisms of cytoplasmic Ca2+ clearance assessed following instantaneous flash photolytic release of Ca2+ into
the cytoplasm.
Results: We found no differences in airway smooth muscle cell basal intracellular Ca2+ concentrations,
bradykinin-stimulated IP3 accumulation or intracellular Ca
2+ responses. Quantification of SERCA2 mRNA or
protein expression levels revealed no differences in ASM cells obtained from subjects with asthma compared
to non-asthmatic controls. We did not identify differences in intracellular calcium kinetics assessed by flash
photolysis and calcium uncaging independent of agonist-activation with or without SERCA inhibition.
However, we did observe some correlations in subjects with asthma between lung function and the different
cellular measurements of intracellular Ca2+ handling, with poorer lung function related to increased rate of
recovery following flash photolytic elevation of cytoplasmic Ca2+ concentration.
Conclusions: Taken together, the experimental results reported in this study do not demonstrate major fundamental
differences in Ca2+ handling between airway smooth muscle cells from non-asthmatic and asthmatic subjects.
Therefore, increased contraction of airway smooth muscle cells derived from asthmatic subjects cannot be fully
explained by altered Ca2+ homeostasis.
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Asthma, a chronic inflammatory disease, remains a major
health care burden affecting over 300 million people
worldwide. There is a subset of patients that do not re-
spond adequately to traditional treatments, highlighting
an urgent need for new therapies [1,2]. Asthma is charac-
terized by variable airflow obstruction and airway hyper-
responsiveness as a consequence of increased airway
smooth muscle (ASM) contractility [3,4]. An increasing
body of evidence supports the view that ASM is funda-
mentally altered in asthma compared to non-asthmatic
controls, suggesting that abnormalities in these structural
cells may also play a critical role in the development of
the abnormal physiology in asthma and may contribute to
the persistent airway inflammation [5-8]. Critically, there
is emerging evidence that ASM from asthmatics is hyper-
contractile, as demonstrated by an increased velocity of
contraction in response to electrical field stimulation at
the single cell level [9] and in cell populations using gel
contraction assays [5,10].
Cytosolic calcium concentration ([Ca2+]i) plays a car-
dinal role in ASM contraction. An increase in intracellular
ASM [Ca2+]i is likely to originate from the sarcoplasmic
reticulum of the cell, with evidence of a lesser reliance on
Ca2+-influx across the sarcolemma through voltage-
dependent channels than other muscle types [11-14]. Evi-
dence has accrued to show that ASM calcium homeostasis
is abnormal in asthma, suggesting abnormal [Ca2+]i
handling, signalling or storage, as possible underlying
mechanisms for this hyper-contractility [11,15,16].
Resolution of an increase in [Ca2+]i involves the move-
ment of Ca2+ out of the cell through the sarcolemmal
Ca2+-ATPase or Na+/Ca2+-exchangers, or into the
sarcoplasmic reticulum through the sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA). SERCA2 is the dom-
inant SERCA isoform expressed in ASM, predomin-
antly as the SERCA2B splice variant, and reduced
SERCA2 in ASM from subjects with asthma has been
reported and proposed to prolong the time for [Ca2+]i
to return to baseline following stimulation [11]. To date
abnormalities in [Ca2+]i handling in ASM from asthmatics
have been explored following agonist-induced activation.
Such receptor-dependent changes in [Ca2+]i are often
complex, involving complex signal transduction mecha-
nisms that can modulate release and re-uptake of [Ca2+]i
at multiple loci. Flash photolysis allows a ‘caged’ form
of calcium to be released in a controlled, time-resolved
manner to investigate [Ca2+]i recovery independently of
a need for agonist addition [17]. Furthermore by
pharmacological inhibition of SERCA activity it is pos-
sible to assess the rates of movement of Ca2+ across the
sarcoplasmic reticular and/or sarcolemmal membranes
to determine if potential asthma-related abnormalities
in [Ca2+]i handling are observed independently of theneed to perturb Ca2+ homeostasis via receptor-mediated
mechanisms.
We hypothesized that Ca2+ handling is abnormal in
ASM from subjects with asthma. To test our hypothesis
we compared in primary ASM cells from subjects with
asthma and non-asthmatic controls: (i) bradykinin-induced
changes in intracellular calcium [Ca2+]i; (ii) SERCA expres-
sion, (iii) agonist-stimulated changes in inositol 1,4,5-tris-
phosphate (IP3) accumulation, and (iv) [Ca
2+]i kinetics
assessed following release of a Ca2+ load into the cytoplasm
by flash photolysis and uncaging.
Methods
Subjects and cells
Asthmatic subjects (n = 20) and non-asthmatic controls
(n = 18) were recruited from Leicester, UK. Asthma se-
verity was defined by Global Initiative for Asthma
(GINA) treatment steps (mild-moderate GINA 1–3, se-
vere GINA 4–5) [4]. Primary ASM cells were isolated
from bronchial biopsies and used at passages 2–5. The
study was approved by the Leicestershire Ethics Com-
mittee and patients gave their written informed consent.
Intracellular Ca2+ imaging
To measure changes in [Ca2+]i, ASM cells plated at
sub-confluence on coverslips were loaded with 2 μM
Fura-2 AM (Molecular Probes/Thermo Fisher Scientific)
in the presence of 2.5 mM probenecid (Sigma-Aldrich)
and 0.04% w/v pluronic F127 (Molecular Probes/Thermo
Fisher Scientific), and visualized using an inverted epi-
fluorescence microscope (Nikon Diaphot 200). Changes in
Fura-2 fluorescence (F) intensity were measured as a ratio,
R, where R = F340 nm/F380 nm, such that R increases as [Ca
2+]i
increases [18]. Bradykinin (1 μM) was added to ASM cells
via perfusion (at 5 mL min−1) in physiological saline solu-
tion (118.4 mM NaCl, 4.7 mM KCl, 2.0 mM CaCl2,
1.2 mMMgCl2, 11.1 mM glucose, 10 mM HEPES, pH 7.4)
at 37°C.
Real-time reverse transcription-polymerase chain reaction
Real-time reverse transcription-polymerase chain reac-
tion was performed (SuperScript Vilo cDNA synthesis
kit, Express SYBR-GreenER qPCR Supermix Universal;
Invitrogen). Relative quantification was done using the
comparative 2-ΔΔCt method [19] and expressed as fold
change. The internal normalizer gene was 18S rRNA
amplified with 18S primer forward (h18SRNA.891 F:
GTTGGTTTTCGGAACTGAGG) and 18S reverse pri-
mer (h18SRNA.1090R: GCATCGTTTATGGTCGGAAC);
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ASM cell monolayers in 24 well plates were stimulated
with different concentrations of bradykinin (0.001-10 μM).
Preliminary experiments demonstrated that IP3 accumu-
lated rapidly after bradykinin addition and was maximal at
10 sec. Incubations were terminated by rapid aspiration
and addition of trichloroacetic acid (0.5 M). Acid extracts
were neutralized and IP3 accumulation measured using a
competitive binding assay as described previously [20].
IP3 accumulation is expressed as pmol mg
−1 of cell protein.
Flash photolysis/Ca2+ uncaging
ASM cells plated at sub-confluence on coverslips were
co-loaded with 2 μM Fluo-4 AM and 2.5 μM nitro-
phenyl-EGTA AM (NP-EGTA AM; Invitrogen [18]) in the
presence of 2.5 mM probenecid and 0.04% w/v pluronic
F127 in physiological saline solution (see above for com-
position). Ca2+ transients were monitored using an
Olympus confocal laser scanning inverted microscope
(FV1000). The single scan head was used to monitor
changes in [Ca2+]i by detecting fluo-4 fluorescence with
the 488 nm line of a multi-line argon laser (at ~2% max-
imum output) using ‘round-trip’ mode, with emission
occurring at 528 nm and a wide confocal aperture set-
ting of 374 μm. Near instantaneous switching allows
photo-activation/uncaging, with a 405 nm laser flash
without bleaching or response saturation, then switching
back to 488 nm monitoring to capture the subsequent re-
covery of the cell towards basal [Ca2+]i [17,21]. Intensity-
time traces, with an image time interval of 32.77 ms,
extending over 26 s were acquired with a × 60/1.2 NA
oil-immersion objective with × 6 optical zoom. Uncaging
pulses of the same intensity were delivered with the
405 nm laser (100%) for 300 ms in ‘tornado’ mode in a re-
gion of interest of diameter 15 pixels, selected in an area
of the cytoplasm away from the nucleus. Each cell tested
was only flashed once. On the microscope stage, cover-
slips were placed into a 1 mL chamber of an open perfu-
sion microincubator (PDMI-2, Harvard Apparatus). Cells
were maintained at 37°C and perfused at a rate of
3.6 mL min−1; where indicated cyclopiazonic acid (CPA,
10 μM, Sigma-Aldrich) was added to the perfusion solu-
tion. Intensity-time curves were analysed by performing a
non-linear two phase exponential curve fit with a recovery
rate K (s−1) derived for each trace. Mean K values were
calculated for each donor/subject and comparison made
between asthma and health/normal. Control experiments
were performed using cells loaded with Fluo-4 AM only
(no NP-EGTA AM) to confirm that the 405 nm flash did
not perturb [Ca2+]i per se.
Assessment of ASM contraction by collagen gel analysis
Collagen gels (299 μl of collagen (Inamed Biomaterials),
37 μl of 10X DMEM (Invitrogen), 20 μl of sodiumbicarbonate (Invitrogen) were impregnated with 0.25 ×
106 ASM cells resuspended in 144 μl of serum-free
medium with stimulus as required. The gels were
added to 24-well plates (PBS/0.5% BSA) and left to
polymerize at 37°C for 90 min. The gels were then de-
tached and suspended in 500 μl of serum-free medium
with stimulus as required. Bradykinin (Sigma-Aldrich)
was added to appropriate wells to a final concentration
of 1nM, with photographs taken at regular intervals up
to 1 hour. The surface area of each gel was measured
at each time point using ImageJ (http://rsb.info.nih.gov/ij)
by a blinded observer.
Statistical analysis
GraphPad Prism (version 6, GraphPad Software, San
Diego) and IBM SPSS version 20 (SPSS, Inc., Chicago)
were used to perform statistical analysis. Mean (standard
error of the mean [S.E.M.]) was used to present para-
metric data, while median (interquartile ranges [IQR])
was used for non-parametric data. Comparisons between
disease states used unpaired Student’s t-tests for para-
metric data, or Mann–Whitney tests for non-parametric
data. Correlations were performed using either Pearson
or Spearman of parametric and non-parametric data,
respectively. A P value less than 0.05 was considered
statistically significant.
Results
The clinical characteristics of the ASM donors are as
shown in Table 1. An example trace showing the time-
course of the [Ca2+]i response following bradykinin
addition is shown in Figure 1A. The average baseline
[Ca2+]i was determined for each donor used (Figure 1B)
where a minimum of 5 cells per donor were analysed.
No differences in F340/F380 ratio were found between
health and disease (0.68 ± 0.02 and 0.64 ± 0.02, respect-
ively; p = 0.15; Figure 1B), or indeed between ASM cells
obtained from subjects with mild/moderate or severe
asthma (0.65 ± 0.05 and 0.64 ± 0.02, respectively; p = 0.83;
Figure 1B). When baseline [Ca2+]i levels were correlated
with FEV1% predicted and FEV1/FVC%, no correlations
were identified (r = −0.03, p = 0.92 and r = 0.11, p = 0.74,
respectively). Following addition of bradykinin (1 μM), the
change in [Ca2+]i (ΔR) was not different between non-
asthmatic and asthmatic donors (change in F340/F380 ratio:
0.17 ± 0.01 and 0.16 ± 0.01, respectively; p = 0.61; Figure 1C),
or between mild/moderate and severe asthma (0.16 ± 0.01
and 0.16 ± 0.02, respectively; p = 0.80; Figure 1C). The re-
sults for agonist-stimulated changes in [Ca2+]i did not cor-
relate with FEV1% predicted and FEV1/FVC% (r = −0.21,
p = 0.56 and r = −0.19, p = 0.60, respectively). The area
under the curve (AUC) values measured following brady-
kinin stimulation also did not significantly differ between
health and disease (8.24[5.63-13.20] and 6.97[6.05-7.96],
Table 1 Clinical and functional characteristics of subjects
Characteristic Normal Mild-moderate asthma GINA 1-3 Severe asthma GINA 4-5
Number 18 9 11
Age 48 (4.2) 43 (5.6) 48 (3.9)
Male/Female 10/8 3/6 9/2
Smoking status
Never/Ex/Current 12/2/4 7/1/1 5/2/4
Pack years+ 29.0 (12.2) 5 (0.0) 19.5 (8.4)
FEV1% predicted 97.0 (2.9) 89.1 (7.5) 95.2 (4.3)
FEV1/FVC% 79.8 (1.7) 71.9 (3.3)* 69.6 (2.1)*
Treatments
LABA (% of patients) 0 11 100
ICS (% of patients) 0 67 100
Dose (bdp) - 533.3 (84.3) 1636 (152.1)
OCS (% of patients) 0 0 36
Dose (mg/day) - - 8.8 (0.7)
Data are mean (SEM), *p < 0.05 compared to normal group. +Pack years refer to those subjects with a smoking history. FEV1, forced expiratory volume in one
second; FVC, forced vital capacity; LABA, long-acting β2 adrenoceptor agonist; ICS, inhaled corticosteroid; OCS, oral corticosteroid.
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ate and severe asthma (6.97[6.27-7.05] and 8.67[6.03-
9.72], respectively; p = 0.87; Figure 1D). These data also
did not correlate with FEV1% predicted and FEV1/FVC%
(r = −0.06, p = 0.86 and r = −0.06, p = 0.86, respectively).
Finally, the rate of recovery following administration of
bradykinin did not differ between ASM cells from non-
asthma and asthma subjects (0.02[0.02-0.02] and 0.02
[0.02-0.03], respectively; p > 0.99; Figure 1E), or between
mild/moderate and severe asthma (0.02[0.02-0.04] and
0.03[0.02-0.03], respectively; p = 0.17; Figure 1E).
The relative expression of SERCA2A/B/C mRNA was
assessed in 10 non-asthmatic control subjects and 13 pa-
tients with asthma (Figure 2A). Expression was not found
to alter between health and disease (1.09[0.90-1.16] and
0.97[0.85-1.26], respectively; p = 0.60; Figure 2A), or be-
tween mild/moderate and severe asthma (0.97[0.77-1.10]
and 1.06[0.86-1.37], respectively; p = 0.62; Figure 2A).
There was no correlation either with FEV1% predicted
and FEV1/FVC% (r = 0.37, p = 0.22 and r = −0.29, p = 0.32,
respectively). Example western blots showing total
SERCA2 protein and β-actin in ASM cells derived from
four asthma patients and three non-asthmatic donors are
shown in Figure 2B. Densitometry of total SERCA2 im-
munoreactivity from western blots showed that there was
no significant difference in SERCA2 protein expression
in normal (n = 10) compared to asthma (n = 10) ASM
cell donors (106 ± 7 and 107 ± 5, respectively; p = 0.90;
Figure 2C). Differences in protein expression were not
found between asthma GINA 1–3 and GINA 4–5 (107 ± 7
and 109 ± 10, respectively; p = 0.84; Figure 2C). In addition,
these data do not correlate with FEV1% predicted andFEV1/FVC% (r = −0.07, p = 0.85 and r = −0.01, p = 0.99,
respectively).
Concentration-dependent IP3 accumulation responses
to bradykinin were assessed in ASM cells derived from
8 non-asthmatic and 11 asthmatic patients. Typical
concentration-response curves are shown for ASM
cells obtained from a non-asthmatic or an asthmatic pa-
tient (Figure 3A). The bradykinin concentrations causing
a half-maximal increase in IP3 accumulation (EC50) were
not significantly different between non-asthmatic and
asthmatic smooth muscle donors (−log EC50 (M): 7.17 ±
0.11 and 7.22 ± 0.10, respectively; p = 0.74; Figure 3B), nor
between mild/moderate and severe asthma (7.40 ± 0.09 and
7.06 ± 0.14, respectively; p = 0.08). No correlation was
found with FEV1% predicted and FEV1/FVC% (r = −0.38,
p = 0.15 and r = −0.48, p = 0.14, respectively). The increase
in IP3 accumulation (basal-to-peak; ΔIP3) following stimu-
lation was not significantly different between health and
disease (ΔIP3 (pmol mg
−1 protein): 631 ± 68 and 647 ± 54,
respectively; p = 0.86; Figure 3C). Accumulation was not
found to differ either between asthma GINA 1–3 and
GINA 4–5 (576 ± 68 and 707 ± 77, respectively; p = 0.25).
Maximal changes in IP3 accumulation stimulated by
bradykinin did not correlate with FEV1% predicted and
FEV1/FVC% (r = 0.01, p = 0.98 and r = −0.02, p = 0.96,
respectively).
Comparisons of [Ca2+]i recovery rates following Ca
2+
uncaging in the absence or presence of SERCA inhib-
ition were made in ASM cells from patients with asthma
or non-asthmatic controls (example traces shown in
Figure 4A). There was no significant difference in the mean
Ca2+ uncaging recovery rate between health and disease
Figure 1 Responses of ASM cells isolated from asthmatic and non-asthmatic subjects to bradykinin addition. (A) Representative graph
showing a [Ca2+]i response to bradykinin (1 μM). Measurements taken from these Ca2+ responses were mean change in F340 nm/F380 nm ratio (ΔR),
baseline Ca2+ concentration (expressed as F340 nm/F380 nm ratio), area under the curve (AUC), and the rate of decline from the peak Ca
2+
response. The baseline [Ca2+]i (B), peak increase in [Ca
2+]i following bradykinin stimulation (C), AUC during the agonist addition (D), and rate of
decline in [Ca2+]i from the peak bradykinin-stimulated response (E) were measured for each ASM cell donor across a range of cells (6–40 cells per
donor) and the average value for each variable plotted for non-asthmatic and asthmatic donors. Symbol key: filled circles: GINA 1–3; open circles:
GINA 4–5; filled squares: non-asthmatic donors. Parametric data (B, C) displayed as mean (SEM) and analysed by Student’s t-test. Non-parametric
data (D, E) displayed as median (IQR) and analyzed using Mann–Whitney.
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−1): 3.31 ± 0.46
and 3.89 ± 0.58, respectively; p = 0.45; Figure 4B), or
when SERCA was inhibited, (K+CPA (s
−1): 1.43 ± 0.23
and 1.29 ± 0.15, respectively; p = 0.60; Figure 4C). Simi-
larly, no differences were seen in recovery rates between
mild/moderate and severe asthma in the absence (K-CPA:
3.80 ± 0.88 and 3.99 ± 0.83, respectively; p = 0.88) or pres-
ence (K+CPA: 1.24 ± 0.25 and 1.34 ± 0.19, respectively; p =
0.77; Figure 4C) of SERCA inhibition. The difference be-
tween K-CPA and K+CPA (ΔK) values in ASM cells from
non-asthmatic and asthmatic patients did not reveal any
differences (ΔK: 1.88 ± 0.51 and 2.61 ± 0.49, respectively;
p = 0.32), nor was there a difference between asthma
GINA classification 1–3 and 4–5 (ΔK: 2.56 ± 0.76 and
2.65 ± 0.69, respectively; p = 0.93).Correlations were observed in the subjects with asthma
between lung function and Ca2+ uncaging recovery rates
with and without SERCA inhibition by CPA (Figure 5).
There was a trend correlating the mean Ca2+ uncaging re-
covery rate with FEV1% predicted (rs = −0.565, p = 0.053;
Figure 5A), which was no longer observed when SERCA
activity was inhibited (rs = −0.244, p = 0.423; Figure 5C). A
trend was also observed between the FEV1/FVC% and Ca
2+
uncaging recovery rates (rs = −0.518, p = 0.085; Figure 5B),
which was statistically significantly correlated when
SERCA activity was inhibited (rs = −0.652, p = 0.024;
Figure 5D). When the difference between the mean
Ca2+ uncaging recovery rates with and without CPA
(ΔK) was compared with FEV1% predicted, there was again
a significant negative correlation (rs = −0.647, p = 0.023;
Figure 2 Quantification of mRNA abundance and protein expression
of SERCA2 in ASM cells from asthmatic and non-asthmatic subjects.
(A) The relative expression of SERCA2a/b/c mRNA normalized to 18S
rRNA was not significantly different (Student’s t-test) in asthma (n = 13)
compared to normal (n = 10) ASM donors. (B) An example western
blot showing total SERCA2 protein and β-actin immunoreactivities in
ASM cells from four asthma (A) and three normal (N) donors. (C)
Densitometry of total SERCA2 immunoreactivity from western blots
shows that there is no significant difference (Student’s t-test) in SERCA2
protein expression (normalized to β-actin expression) in asthma
(n = 10) compared to normal (n = 10) ASM cell donors. Symbol key: filled
circles: GINA 1–3; open circles: GINA 4–5; filled squares: non-asthmatic
donors. Non-parametric data (A) displayed as median (IQR) and analyzed
using Mann–Whitney. Parametric data (C) displayed as mean (SEM) and
analyzed by Student’s t-test.
Figure 3 Concentration-dependent IP3 accumulation responses to
bradykinin in ASM cells derived from asthmatic and non-asthmatic
donors. (A) Representative examples of bradykinin concentration-response
curves obtained for ASM cell monolayers from one asthmatic (○) and one
non-asthmatic (▼) donor. (B) Graph showing the bradykinin concentrations
causing a 50% of the maximal IP3 accumulation (shown as –log EC50 (M)
values) in normal (n = 8) and asthmatic (n = 11) ASM donors. (C) The
increase in IP3 accumulation following stimulation by a maximally effective
concentration of bradykinin (10 μM) for ASM cells from non-asthmatic
(n = 8) and asthmatic (n = 11) donors. Symbols key: filled circles: GINA 1–3;
open circles: GINA 4–5; filled squares: non-asthmatic donors. Data are
shown as mean (SEM) and analyzed by Student’s t-test.
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Figure 4 Assessing the recovery of [Ca2+]i following Ca
2+-uncaging in ASM cells derived from asthmatic and non-asthmatic donors.
(A) Representative examples of changes in [Ca2+]i on photolysis of the NP-EGTA Ca
2+ cage and the subsequent rate of recovery to pre-uncaging
levels of [Ca2+]i. Changes in [Ca
2+]i are shown for ASM cells in the absence (blue line) or presence (green line) of the SERCA inhibitor, CPA
(10 μM). Inset example photographs of Ca2+ uncaging using a confocal microscope before (i), during (ii) and after (iii) the 405 nm laser flash.
(B) Mean Ca2+ uncaging recovery rates (K-CPA) without SERCA inhibition in ASM cells from normal (n = 10) and asthma (n = 10) donors. (C) Mean
Ca2+ uncaging recovery rates when SERCA is inhibited (K+CPA) in ASM cells from normal (n = 10) and asthma (n = 12) donors. (D) The difference
between K-CPA and K+CPA (ΔK), which represents primarily trans-plasmalemmal efflux of Ca
2+ in ASM cells, is also plotted for each normal (n = 10)
and asthmatic (n = 12) donor. Symbol key: filled circles: GINA 1–3; open circles: GINA 4–5 filled squares: non-asthmatic donors. Data are shown as
mean (SEM) and analyzed by Student’s t-test.
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p = 0.252; Figure 5F).
In 17/38 ASM donors, agonist-induced contraction
was assessed. The ASM from asthmatic was hypercontrac-
tile (mean difference in area under the curve contraction ±
SEM; 5127 ± 140; 4274 ± 207; p = 0.023; non-asthmatic
compared to asthmatic respectively; Figure 6A and B).
Area under the curve contraction was not related to
ΔR, but was related to K and ΔK (r = 0.04; p = 0.93;
rs = −0.691; p = 0.023; rs = −0.618; p = 0.048 respectively;
data not shown).Discussion
Here we have studied [Ca2+]i handling by low passage
primary ASM cells from subjects with asthma compared
to non-asthmatic controls. Our findings demonstrate no
differences in basal [Ca2+]i, agonist-induced peak [Ca
2+]i
responses or recovery following agonist activation.
Concentration-dependent accumulations of the second
messenger IP3 in response to bradykinin addition were
not different in ASM cells from subjects with asthma
versus non-asthmatic controls, although there was a small,
significant increase in maximal bradykinin-stimulated IP3
Figure 5 Correlations of rates of recovery following Ca2+ uncaging in ASM cells with clinical lung function parameters in respective
patient donors. Recovery rates compared to the FEV1% predicted (A, C, E) and FEV1/FVC% (B, D, F) are shown in the absence of inhibitor
(−CPA, ●, A, B), in the presence of CPA (+CPA, ○, C, D), or for the difference between –CPA and + CPA recovery rates (ΔK, ▲, E, F). Data were
analyzed by Spearman correlation (95% confidence interval).
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(GINA 1–3) asthma patients were compared. We did not
identify any differences in SERCA2 mRNA or protein ex-
pression. [Ca2+]i kinetics assessed by flash photolysis and
calcium uncaging independent of agonist-activation again
did not demonstrate differences in rates of recovery of
[Ca2+]i either with or without SERCA inhibition. However,
we did observe correlations in the subjects with asthma
between lung function and [Ca2+]i rate of recovery follow-
ing flash photolysis with poorer lung function relating toan increased rate of recovery. Taken together this study
does not support a fundamental difference in [Ca2+]i
handling in ASM from subjects with asthma compared to
non-asthmatic controls per se, but does not exclude a pos-
sible contribution in specific phenotypes, such as those
with impaired lung function, as suggested here by subtle
differences in [Ca2+]i recovery rates.
Our findings of no disease-related differences in agonist-
induced evoked changes in [Ca2+]i conflicts with work pub-
lished previously [11,15,16]. Mahn and colleagues reported
Figure 6 Collagen gel contraction assay of human airway smooth muscle cells. (A) Percentage contraction of collagen gels impregnated
with airway smooth muscle from donors who are not asthmatic (n = 5) and donors with asthma (n = 12) over 1 hour following stimulation with 1 nM
bradykinin. (B) Area under the curve gel contraction. Symbol key: filled circles: GINA 1–3; open circles: GINA 4–5; filled squares: non-asthmatic donors.
Data are shown as mean ± SEM and analysed by Student’s t-test.
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of bradykinin [11], a reduced response to ryanodine (1 μM)
and thapsigargin (0.1 μM) in ASM cells from asthmatic ver-
sus non-asthmatic donors. Similarly, Trian et al. reported a
reduced [Ca2+]i response to acetylcholine (10 μM) or hista-
mine (10 μM) in ASM cells from asthmatic subjects [16].
Interestingly, in contrast to our report, the healthy control
and asthma subjects were not age matched and whether
calcium handling is altered by age of the donor is unknown.
We have been unable to confirm these earlier findings and
did not observe associations between agonist-induced
[Ca2+]i peak or rate of recovery with severity of disease de-
fined by GINA treatment steps, nor with lung function. Our
study had 80% power to observe a 0.05 difference between
health and disease in [Ca2+]i (ΔR) following bradykinin acti-
vation. Mahn et al. reported [Ca2+]i (ΔR) of 0.07 and 0.12
between ASM from non-asthmaticsubjects versus those
with either mild or moderate asthma, respectively [11].
Therefore, our study had sufficient power to observe the dif-
ferences reported previously. Thus, it would seem likely that
the differences found here compared to earlier reports re-
flect the heterogeneity of the disease and indicate that
changes in [Ca2+]i in response to agonist might be altered
in some asthmatics. Therefore, whether altered [Ca2+]i
handling is typically altered in asthma requires further
study in a larger population.
In addition to our inability to replicate earlier reports
of differences in agonist-evoked changes in [Ca2+]i wewere also unable to demonstrate differences in SERCA2
expression, either at the mRNA or protein levels. Mahn
et al. found reduced expression of both mRNA and
protein in primary ASM cells and reduced expression in
ASM in vivo in tissue sections of endobronchial biopsies,
in both moderate and severe asthmatics compared to
non-asthmatic controls [11]. We did not investigate
SERCA2 expression in tissue and therefore cannot
exclude the possibility of differential expression in vivo,
but our findings do not support a fundamental change
in SERCA expression in disease, nor a relationship with
disease severity determined by either treatment require-
ment or lung function. Again our study was sufficiently
powered to observe the differences described by Mahn
et al. and therefore, the most plausible explanation is
that decreased SERCA expression is not a consistent
feature of ASM from subjects with asthma.
We report for the first time a comparison of the con-
centration dependency and magnitude of changes in the
Ca2+-mobilizing second messenger IP3 in response to
bradykinin in ASM cells from subjects with asthma
compared to health. We did not find any differences
between health and disease, or disease severity. Here we
also extended the exploration of intracellular [Ca2+]i
handling to investigate the differences in ASM cells from
subjects with asthma and non-asthmatic controls inde-
pendent of agonist. [Ca2+]i kinetics assessed by flash
photolysis and calcium uncaging independent of agonist-
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of recovery of [Ca2+]i either with or without SERCA in-
hibition. Interestingly, we did observe correlations in the
subjects with asthma between lung function and rates of
recovery of [Ca2+]i following flash photolysis. Those
asthmatics with poorer lung function had greater rates
of [Ca2+]i recovery. This again conflicts with the report
from Mahn et al., which suggests that rates of recovery
are reduced in asthma [11,15]. Similar correlations
between spontaneous calcium oscillation frequency and
lung function were observed previously [22]. Whether
there is a common mechanism between spontaneous
oscillations and rate of recovery in [Ca2+]i following flash
photolysis requires further investigation. However, al-
though the correlations reported here are intriguing,
they are only observed in those ASM cells from subjects
with asthma and there were no differences in uncaging
[Ca2+]i rate of recovery between asthma and health,
questioning whether these relationships are important.
In contrast to the inconsistency of the observations
relating to [Ca2+]i handling in ASM cells from subjects
with asthma, we and others have consistently found that
primary ASM cells from asthmatics are hyper-contractile
[5,9-11]. Contraction in ASM is driven by [Ca2+]i origin-
ating from the sarcoplasmic reticulum stores, therefore,
the hyper-contractility seen in asthma is likely to be due
to abnormalities in [Ca2+]i handling, Ca
2+ sensitivity or
changes to the contractile machinery. Since we have not
shown here any intrinsic abnormality in [Ca2+]i or
SERCA2 in ASM cells derived from asthmatic patients
when compared with non-asthmatic subjects, we must
consider alternative mechanisms. Myosin light-chain
kinase (MLCK) is a major player in this Ca2+/contrac-
tion pathway and indeed others have found expression
of MLCK to be increased [11,23]. Up-regulation of the
Ca2+-independent rhoA/rho kinase signalling pathway
leads to inhibition of myosin light-chain phosphatase
resulting in increased levels of phosphorylated myosin
light-chains and increased ASM contraction force at a
given increase in [Ca2+]i [24]. Abnormalities within this
pathway have been reported in animal models [25,26].
Beyond the Ca2+/contraction pathway, increased produc-
tion of reactive oxygen species (ROS) can damage tissue;
indeed, the oxidative burden is increased in asthma.
Nicotinamide adenine dinucleotide phosphate oxidase 4
(NOX4), an important source of ROS, is increased in
asthmatics and hyper-contractility of ASM from asth-
matic patients, seen in gel-contraction assays, could be
abolished following the addition of NOX4 inhibitors or
transfection with small interfering RNAs targeting
NOX4 [5]. Pathways, such as cAMP signalling that me-
diate bronchorelaxation, for example cAMP dependent
PKA inhibits MLCK by reducing its affinity for Ca2+/
CaM (reviewed in [27]), may also be differentiallyregulated in ASM from subjects with asthma versus
health. Furthermore, phosphodiesterase (PDE)4 and
prostaglandin (PG)E2 are differentially expressed in
ASM from asthmatic and healthy donors, and might
contribute to increased contration in asthma [28,29].
These and other mechanisms need to be explored
further in future studies.
Our study has a number of potential limitations. We
have used primary ASM cells and therefore whether
important mechanisms present in vivo persist in culture
is uncertain. However, our ability to observe hyper-
contractility in primary ASM from asthmatics does
suggest the mechanism driving this abnormality persists
in vitro and therefore our inability to demonstrate al-
tered [Ca2+]i handling remains important. Perhaps more
critical is the heterogeneity of asthma and even though
our study has sufficient power to observe large differences
in [Ca2+]i handling we might have failed to observe small,
albeit important, differences in specific phenotypes of
asthma. For example, our intriguing observations of corre-
lations between lung function and [Ca2+]i rates of recovery
following NP-EGTA Ca2+ uncaging might reflect import-
ant associations in a sub-group of asthmatics.
Conclusions
In summary, we have not shown major fundamental
differences in Ca2+ handling between ASM from subjects
with and without asthma, in contrast to previous reports
[11,16], we conclude that differences in contraction
between asthmatic and non-asthmatic subject-derived
primary ASM cells cannot be fully explained by altered
[Ca2+]i homeostasis in asthma.
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